LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT:IMUC) announced the expansion of its relationship with Progenitor Cell Therapy, LLC (“PCT”), a subsidiary of NeoStem, Inc. (NASDAQ:NBS), for current good manufacturing practices (cGMP) services for ImmunoCellular’s dendritic cell-based vaccines. PCT currently manufactures ICT-121, a dendritic cell vaccine targeting CD133 cells, in a phase I clinical trial for recurrent glioblastoma multiforme (GBM) pursuant to a Services Agreement between the companies. PCT also manufactured phase II clinical supplies of ICT-107, a dendritic cell-based vaccine targeting six tumor-associated antigens for newly diagnosed GBM.
Help employers find you! Check out all the jobs and post your resume.
